ASH 2022 | The role of chemotherapy in Hodgkin lymphoma
Yago Nieto
• 11 Dec 2022
Yago Nieto, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the use of chemotherapy in Hodgkin lymphoma (HL) treatment, which is typically employed in combination with novel agents such as brentuximab vedotin or checkpoint inhibitors. However, Prof. Nieto highlights that frail patients may require alternative chemotherapy-free approaches. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Affimed: Other: Scientific advisory Board, Research Funding; Secura Bio: Research Funding; Astra Zeneca: Research Funding.
